Dr. Steven Rosenfeld, MD

Dr. Rosenfeld practices at Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic.

Dr. Rosenfeld's NPI, 1952406381, was assigned on September 13, 2006. Dr. Rosenfeld graduated from Feinberg School of Medicine in 1985. Dr. Rosenfeld holds Florida license ME131340.

Dr. Rosenfeld's primary practice is Mayo Clinic Hospital, at 4500 San Pablo Rd, Jacksonville, FL 32224 in Duval County. The practice phone is (904) 953-2000.

Dr. Rosenfeld's primary practice is Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic. The medical group on file is Mayo Clinic Jacksonville.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rosenfeld practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rosenfeld's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rosenfeld is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Rosenfeld's licenses on file in 5 states: Florida, Ohio, New York, Alabama and North Carolina.

Dmand AI lists breast cancer, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Rosenfeld treats.

CMS data shows 116 Medicare services from Dr. Rosenfeld across 4 procedure codes in 2024, all of them office visits, for 78 Medicare patients. Medicare paid $9,252 for them. Every service was in an office.

CMS counts 78 Medicare patients who saw Dr. Rosenfeld in 2024. The largest group is 65 to 74, with 42 patients. 75% of them have high cholesterol, and 60% have high blood pressure. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rosenfeld's median patient age at 66, with 48% women.

In 2024, Dr. Rosenfeld wrote 127 Medicare Part D claims for 27 patients. 86% of them were for generic drugs. CMS names the drug for 58 of them, across 2 drugs with 11 or more claims each, at $1,399 in total drug cost. In 2023, CMS named 45 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Rosenfeld for performance year 2024, reported as part of a group. Dr. Rosenfeld accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rosenfeld as offering telehealth.

Dmand AI links 125 papers to Dr. Rosenfeld, published from 2001 to 2025. 2019 was the busiest year, with 7. The most frequent topics are Kinetics, Brain Neoplasms and Kinesins. Dr. Rosenfeld has published most often in J Biol Chem. Dr. Rosenfeld's most frequent co-authors are Peter Daniel Canoll, MD, PhD, Jeffrey N. Bruce, MD and Matei A. Banu, MD.

Dmand AI links Dr. Rosenfeld to 3 clinical trials, 2 of them phase 1/2 studies. Conditions studied include Oligodendroglioma, Glioblastoma and Gliosarcoma. TransMolecular sponsors the most, 2.

CMS Open Payments shows 2 general payments to Dr. Rosenfeld from 1 drug or device company in 2019. Food and beverage make up the largest share, 100% of the total. Dendreon Pharmaceuticals LLC paid the most, $37.

Dmand AI lists 5 awards for Dr. Rosenfeld, most recently America's Top Doctors in 2014.

Dr. Rosenfeld graduated from Feinberg School of Medicine in 1985.

Dr. Rosenfeld is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. POS plans come from the most carriers, 4. Check the plan with the practice before a visit.